Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients

Clinical Research in Cardiology

Volumn 95, Issue 5, 2006, Pages 261-269

  Picard, F ^a   Brehm, M ^a   Fassbach, M ^a   Pelzer, B ^a   Scheuring, S ^a   Kury P ^a   Strauer, B E ^a   Schwartzkopff, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Collagenases; Dilated cardiomyopathy; Matrix metalloproteinase inhibitors; Matrix metalloproteinases; Quantitative RT PCR; Ventricular remodeling

Indexed keywords

COLLAGEN; COMPLEMENTARY DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE BIOPSY; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MALE; MORPHOMETRICS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; ENDOCARDIUM; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33646512047     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-006-0373-z     Document Type: Article

References (46)

1. Andersson B, Caidahl K, Waagstein F, Olofsson E (1995) Idiopathic dilated cardiomyopathy among Swedish patients with congestive heart failure. Eur Heart J 16:53-60
2. Becker R, Haass M, Ick D, Krüger C, Bauer A, Senges-Becker JC, Voss F, Hilbel T, Niroomand F, Katus H, Schoes W (2003) Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy. Basic Res Cardiol 98(4):259-266
3. Borg TK, Burgess ML (1993) Holding all together: organization and function(s) of the extracellular matrix of the heart. Heart Fail 8:230-238
4. Chadwick V, Thomas BS, Mytsi L, Coker BA, Zeller JL, Handy JR, Jackson Crumbley A, Spinale FG (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients whith endstage dilated cardiomyopathy. Circ 97:1708-1715
5. Dolley CM, McEwan JR, Henney AM (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868
6. Donay A (2003) Differentielle Genexpression bei der dilatativen Kardiomyopathie. Dissertation: Justus-Liebig-Universität Gießen, S 1108
7. Heid C, Stevens J, Livak K (1996) Real time quantitative PCR. Genome Res 6(10):986-994
8. Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack F, Hagl S, Katus H, Haass M, Otto F, Schnabel PA (2005) Extracellular matrix proteins und matrix metalloproteinases differ between various right and left ventricular sites in endstage cardiomyopathies. Virch Arch 446:369-378
9. Janicki JS (1995) Collagen degradation in the heart. In: Eghbali-Webb M (ed) Molecular biology of collagen matrix in the heart. Austin: Landes, pp 61-76
10. Hongo M, Ryoke T, Schoenfeld J, Hunter N, Dalton R, Clark, Lowe D, Chien K, Ross Jr (2000) Effects of growth hormone on cardiac dysfunction and gene expression on genetic murine dilated cardiomyopathy. Bas Res Cardiol 95(6):431-441
11. Kähäri VM, Saarialho-Kere U (1999) Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31:34-45
12. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG (1995) Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75(14):913-918
13. Kühl U, Noutsias M, Seeberg B, Schultheiss HP (1996) Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 75:295-300
14. Kubo H, Margulies K, Piacentino V, Gaughan John, Houser S (2001) Patients with end-tage congestive heart failure treated with β-Adrenergic receptor antagonist have improved ventricular myocyte calcium regulatory protein abundance. Circ 104:1012-1018
15. Lamparter, Maisch (2000) Bedeutung von Matrix Metalloproteinasen bei kardiovaskulären Erkrankungen. Z Kardiol 89:949-957
16. Li YY, Feldman A, Sun Y, Mc Thierman CF (1998) Differential expression of tissue Inhibitors of metalloproteinases in the failing human heart. Circ 98:1728-1734
17. Malberg H, Bauernschmitt R, Meyerfeld U, Schirdewan, Wessel N (2003) Kurzzeit-Analyse der Herzfrequenzturbulenz versus Variabilitätsparameter und Barorezeptorsensitivität bei Patienten mit dilatativer Kardiomypathie. Z Kardiol 92(7):547-557
18. Maquart F, Pickart L, Laurent M (1988) Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl- lysine-Cu2+. FEES Lett 238:343-346
19. Maquart F, Bellon G, Pasco S, Monboisse J (2005) Matrikines in the regulation of extracellular matrix degradation. Biochimie 87(3-4):353-360
20. Marriott JB, Goldman JH, Keeling PJ, Baig MK, Dalgleish AG, McKenna WJ (1996) Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 75:287-290
21. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM (1996) Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77(9):723-727
22. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-158
23. Nürnberg JH, Butter C, Abdul-Khalig H, Schlegl M, Lange PE (2005) Successful cardiac resynchronization therapy in a 9-year-old boy with dilated cardiomyopathy. Z Kardiol 94(1):44-48
24. Oie E, Yndestad A, Robin SP, Bornerheim R, Asberg A, Attramadal H (2002) Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. Bas Res Cardiol 97(3):239-247
25. Olivetti G, Capasso JMK, Sonnenblick EH, Anversa P (1990) Side to side slippage of myocytes participates in ventricular wall remodeling acurely after myocardial infarction in rats. Circ Res 67:23-24
26. Ohtsuki M, Nomura T, Morimoto S, Hiramitsu S, Uemura A, Kato S, Kato Y, Shirasishi H, Shimokubo J, Yamamoto N, Hishida H (2005) Suppressed expression of GTP cyclohydrolase I mRNA and accelerated expression of inducible nitric oxide synthase mRNA in endomyocardial biopsy specimens from patients with dilated cardiomyopathy. Clin Chem Acta 353:103-107
27. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PC, Kühl U, Schultheiß, HP (1999) Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circ 99:2750-2756
28. Pauschinger M, Chandrasekharan K, Schultheiss HP (2004) Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-/TIMP system. Heart Fail Rev 9:21-31
29. Ratajska A, Cleutjens J (2002) Embryogenesis of the rat heart: the expression of collagenases. Bas Res Cardiol 97(3):189-197
30. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE (2002) Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4:439-444
31. Schwartzkopff B, Ühre B, Ehle B, Lässe B, Frenzel H (1987) Variability and reproducibility of morphological biopsies in hypetrophic obstructizee cardiomyopathie. Z Kardiol 76(3):14-19
32. Siu B, Niimura H, Osborne J, Fatkin D, MacRae C, Solomon S, Benson W, Seidman JG, Seidman C (1999) Familial dilated cardiomyopathy locus maps to chromosome 2q31. Circ 99:1022-1026
33. Spinale FG (2002) Matrix metalloproteinases, regulation and dysregulation in the failing heart. Circ Res 90:520-530
34. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ (2000) A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circ 102:1944-1949
35. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85(4):364-376
36. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82:482-495
37. Strauer BE, Kandolf R, Mall G, Maisch B, Mertens T, Figulla HR, Schwartzkopff B, Brehm M, Schultheiß HP (2001) Myokarditis - Kardiomyopathie, Update 2001. Med Klin 96:608-625
38. Taipale J, Keski-Oja J (1997) Growth factors in the extracellular matrix. FASEB J 11:51-59
39. Tyagi SC (1998) Extracellular matrix dynamics in heart failure: a prospect for gene therapy. J Cell Biochem 68:403-410
40. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ (1996) Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 155:13-21
41. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ (1996) Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 63(2):185-198
42. Tyagi SC, Kumar SG, Banks J, Fortson W (1995) Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 27(10):2177-2189
43. Weber K, Anversa P, Armstrong P, Brilla C, Burnett J, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FAO, Motz WH, Mulvany MJ, Strauer BE (1992) Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20:3-16
44. Woessner JF, Nagase H (2000) Activation of the zymogen forms of MMPs. In: Matrix Metalloproteinases and TIMPs. Oxford University Press, New York, pp 72-86
45. Youn T, Kim H, Oh B (2002) Ventricular remodeling and transforming growth factor 1 mRNA expression after nontranmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade. Basic Res Cardiol 94(4):246-253
46. Zhao M, Zhang H, Robinson TF, Factor SM, Sonnenblick EH (1987) Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional (stunned) but viable myocardium. J Am Coll Cardiol 10:1322-1334